Idioma:

Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters

Edaravone Acute Infarction Study Group

Cerebrovascular diseases (Basel, Switzerland), 2003-01, Vol.15 (3), p.222 [Periódico revisado por pares]

Switzerland: S. Karger AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters
Autor: Edaravone Acute Infarction Study Group
Assuntos: Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Antipyrine - administration & dosage ; Antipyrine - adverse effects ; Antipyrine - analogs & derivatives ; Antipyrine - therapeutic use ; Cerebral Infarction - drug therapy ; Cerebral Infarction - psychology ; Double-Blind Method ; Female ; Free Radical Scavengers - administration & dosage ; Free Radical Scavengers - adverse effects ; Free Radical Scavengers - therapeutic use ; Humans ; Male ; Middle Aged ; Neuropsychological Tests ; Treatment Outcome
É parte de: Cerebrovascular diseases (Basel, Switzerland), 2003-01, Vol.15 (3), p.222
Descrição: Edaravone, a novel free radical scavenger, demonstrates neuroprotective effects by inhibiting vascular endothelial cell injury and ameliorating neuronal damage in ischemic brain models. The present study was undertaken to verify its therapeutic efficacy following acute ischemic stroke. We performed a multicenter, randomized, placebo-controlled, double-blind study on acute ischemic stroke patients commencing within 72 h of onset. Edaravone was infused at a dose of 30 mg, twice a day, for 14 days. At discharge within 3 months or at 3 months after onset, the functional outcome was evaluated using the modified Rankin Scale. Two hundred and fifty-two patients were initially enrolled. Of these, 125 were allocated to the edaravone group and 125 to the placebo group for analysis. Two patients were excluded because of subarachnoid hemorrhage and disseminated intravascular coagulation. A significant improvement in functional outcome was observed in the edaravone group as evaluated by the modified Rankin Scale (p = 0.0382). Edaravone represents a neuroprotective agent which is potentially useful for treating acute ischemic stroke, since it can exert significant effects on functional outcome as compared with placebo.
Editor: Switzerland: S. Karger AG
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 7 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters

Edaravone Acute Infarction Study Group

Switzerland: S. Karger AG

Buscando em bases de dados remotas. Favor aguardar.